A US drug trial on cancer patients cured all and vanished their tumors

A US drug trial on cancer patients cured all and vanished their tumors.

18 rectal cancer patients saw their tumors disappear after receiving immunotherapy without surgery, radiation, or chemotherapy in an experimental study.

The unexpected findings have left doctors and patients ecstatic and optimistic about the future implications.

The study findings were published in The New England Journal of Medicine (June 5).

The patients used a medicine called Dostarlimab for six months and had seen their tumors completely shrink.

There will be no surgery, radiation, or chemotherapy.

Andrea Cercek, a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), Rectal cancer patients have difficulty having surgery, radiation, and chemotherapy.

Patients might be able to avoid the harmful side effects of standard therapies such as bowel and bladder malfunction, incontinence, infertility, and sexual dysfunction by using immunotherapy.

The patients in the study were given a medication called Dostarlimab, which acts as an antibody replacement.

Immunotherapy is when the body’s immune system fights cancer. The researchers wanted to see whether immunotherapy might be used to treat rectal cancer that hadn’t progressed to other body regions.

This study focused on a subgroup of patients with a particular genetic mutation in their tumor.

Dr. Cercek said in a news statement, “We’re seeing an increasing number of young patients with rectal cancer, including participants in our research who are in their twenties. Immunotherapy might be a promising new treatment option for them.”

Over two years, none of the patients’ cancers returned. For cancer patients and oncologists, the experiment yielded positive outcomes. A bigger experiment, however, would be necessary to investigate the reach of this novel therapy fully.